text
"['\n1. 요약재무정보\n가. 연결 재무정보\n1) 요약재무정보(연결)\xa0\n(단위 : 원 )\n구 분\n제64기 3분기\n제63기\n제62기\n[유동자산]\n27,917,162,057\xa0\n22,179,284,235\n32,335,811,726\nㆍ당좌자산\n21,126,043,349\n14,076,873,659\n22,324,638,175\nㆍ재고자산\n6,791,118,708\xa0\n8,102,410,576\n10,011,173,551\n[비유동자산]\n53,330,694,200\n49,926,110,781\n51,753,184,638\nㆍ투자자산\n7,896,376,459\n1,758,505,677\n5,803,907,176\nㆍ유형자산\n32,674,520,038\xa0\n37,192,300,892\n41,668,859,785\nㆍ무형자산\n1,848,131,989\xa0\n2,208,933,367\n2,646,703,007\nㆍ기타비유동자산\n10,911,665,714\n8,766,370,845\n1,633,714,670\n자산총계\n81,247,856,257\n72,105,395,016\n84,088,996,364\n[유동부채]\n16,260,462,822\n11,423,664,047\n14,918,333,308\n[비유동부채]\n7,431,411,840\n8,718,770,938\n6,524,272,722\n부채총계\n23,691,874,662\n20,142,434,985\n21,442,606,030\n[지배기업의 소유주에게 귀속되는 자본]\n57,555,781,668\n51,962,805,680\n64,787,134,464\nㆍ자본금\n59,284,983,000\xa0\n50,899,498,000\n114,267,552,000\nㆍ연결자본잉여금\n3,435,078,941\xa0\n3,227,318,552\n3,227,318,552\nㆍ연결기타자본항목\n4,586,793,082\xa0\n6,039,466,270\n8,630,005,372\nㆍ연결이익잉여금\n(9,751,073,355)\n(8,203,477,142)\n(61,337,741,460)\n[비지배지분]\n199,927\n154,351\n(2,140,744,130)\n자본총계\n57,555,981,595\n51,962,960,031\n62,646,390,334\n매출액\n38,119,963,736\n37,699,312,899\n30,373,353,893\xa0\n영업이익(손실)\n728,990,782\n(11,249,275,255)\n(10,123,767,392)\n연결당기순이익(손실)\n(5,370,598,959)\n(11,644,021,627)\n(30,174,299,094)\n지배회사지분 순이익(손실)\n(5,370,666,595)\n(10,880,761,694)\n(19,505,949,555)\n보통주 기본주당순이익(손실)\n(48)\n(107)\n(112)\n보통주 희석주당순이익(손실)\n(48)\n(107)\n(112)\n연결에 포함된 회사수\xa0\xa0 (단위 : 개)\n2\n2\n2\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.\xa0\xa0\n2)재무제표 재작성- 해당 없음 -\n3) 당기에 신규로 연결재무제표에 포함된 종속기업이나 당기 중 연결재무제표의 작성대상에서 제외된 종속기업은 다음과 같습니다.\xa0 \xa0\n회계기준\n제64기\n제63기\n제62기\n한국채택국제회계기준(K-IFRS)적용 시\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\n4) 연결재무제표 작성 기준- 자세한 사항은 \'3. 연결재무제표 주석\'을 참조 바랍니다.\xa0\n나. 별도 재무정보\n1) 요약 재무정보(별도)\xa0\n(단위 : 원 )\n구 분\n제64기 3분기\n제63기\n제62기\n[유동자산]\n23,148,725,548\n20,352,110,481\n33,043,976,531\nㆍ당좌자산\n19,043,661,350\n16,664,473,420\n26,016,424,616\nㆍ재고자산\n4,068,639,402\n3,629,453,520\n6,884,426,799\nㆍ기타유동자산\n36,424,796\n58,183,541\n143,125,116\n[비유동자산]\n51,911,113,774\n46,373,942,102\n55,039,362,875\nㆍ투자자산\n16,065,399,275\n9,302,804,619\n5,804,691,806\nㆍ유형자산\n23,085,916,796\n26,095,833,271\n31,137,265,312\nㆍ무형자산\n1,848,131,989\n2,208,933,367\n2,646,703,007\nㆍ기타비유동자산\n10,911,665,714\n8,766,370,845\n15,450,702,750\n자산총계\n75,059,839,322\n66,726,052,583\n88,083,339,406\n[유동부채]\n14,186,052,756\n8,894,879,825\n14,334,056,074\n[비유동부채]\n7,431,411,840\n8,718,770,938\n6,233,963,052\n부채총계\n21,617,464,596\n17,613,650,763\n20,568,019,126\n[자본금]\n59,284,983,000\n50,899,498,000\n114,267,552,000\n[자본잉여금]\n3,435,078,941\n3,227,318,552\n3,227,318,552\n[기타자본항목]\n173,053,395\n173,053,395\n183,069,539\n[이익잉여금]\n(9,450,740,610)\n(5,187,468,127)\n(50,162,619,811)\n자본총계\n53,442,374,726\n49,112,401,820\n67,515,320,280\n종속·관계·공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n2020년4월부터2020년12월까지\n2019년4월부터2020년3월까지\n2018년4월부터2019년3월까지\n매출액\n26,037,551,973\n30,480,028,297\n26,717,684,075\n영업이익(손실)\n(2,205,593,570)\n(11,006,657,091)\n(7,106,603,047)\n당기순이익(손실)\n(8,044,558,748)\n(19,053,556,015)\n(21,365,618,595)\n보통주 기본주당순이익(손실)\n(72)\n(187)\n(122)\n보통주 희석주당순이익(손실)\n(72)\n(187)\n(122)\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.(별도 기준)\xa0 \xa0\xa0\xa0 \xa0 \xa0 \xa02) 재무정보 이용상의 유의점 (별도재무제표 기준)- 전기에 제출된 사업보고서의 첨부자료 ""5. 재무제표 주석""을 참조바랍니다.\xa0\n']"
